standard of care in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results FACCT Trial, 2021 (REV) 1.44 [0.59; 3.51]
RECOVERY, 2020 (REV) 0.92 [0.81; 1.03]
SOLIDARITY (WHO study) HCQ, 2020 (REV) 0.84 [0.63; 1.12]
0.91 [0.82 ; 1.02 ] FACCT Trial, 2021 (REV), RECOVERY, 2020 (REV), SOLIDARITY (WHO study) HCQ, 2020 (REV) 3 0% 6,823 moderate not evaluable deathsdetailed results Abd-Elsalam, 2020 (REV) 0.82 [0.24; 2.80]
ARCHAIC -hydroxychloroquine, 2020 (REV) 0.20 [0.01; 7.42]
CCAP-1, 2020 (REV) 1.00 [0.00; 255.63]
Chen, 2020 (REV) 1.78 [0.03; 95.97]
ChiCTR2000030054-HCQ (Chen), 2020 (REV) 1.52 [0.03; 82.26]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV) 0.68 [0.22; 2.09]
Duke university HCQ, 2020 (REV) 1.00 [0.02; 50.40]
Duke University hydroxychloroquine/azithromycine, 2020 (REV) 2.00 [0.05; 78.25]
FACCT Trial, 2021 (REV) 1.04 [0.48; 2.26]
HC-nCoV (Shanghai), 2020 (REV) 1.00 [0.02; 53.89]
NCT04333654, 2020 (REV) 1.80 [0.03; 121.71]
NO COVID-19 (Lyngbakken), 2020 (REV) 1.04 [0.06; 17.13]
NOR-Solidarity (hydroxychloroquine), 2021 (REV) 0.32 [0.03; 3.45]
OAHU-COVID19, 2020 (REV) 0.36 [0.01; 9.70]
PROTECT A, 2020 (REV) 1.98 [0.07; 60.23]
PROTECT B, 2020 (REV) 1.96 [0.16; 23.53]
RECOVERY, 2020 (REV) 0.92 [0.81; 1.03]
REMAP-CAP-HCQ, 2020 (REV) 0.96 [0.46; 2.03]
SOLIDARITY (WHO study) HCQ, 2020 (REV) 0.84 [0.63; 1.12]
Tang, 2020 (REV) 1.00 [0.02; 51.07]
0.91 [0.82 ; 1.01 ] Abd-Elsalam, 2020 (REV), ARCHAIC -hydroxychloroquine, 2020 (REV), CCAP-1, 2020 (REV), Chen, 2020 (REV), ChiCTR2000030054-HCQ (Chen), 2020 (REV), Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV), Duke university HCQ, 2020 (REV), Duke University hydroxychloroquine/azithromycine, 2020 (REV), FACCT Trial, 2021 (REV), HC-nCoV (Shanghai), 2020 (REV), NCT04333654, 2020 (REV), NO COVID-19 (Lyngbakken), 2020 (REV), NOR-Solidarity (hydroxychloroquine), 2021 (REV), OAHU-COVID19, 2020 (REV), PROTECT A, 2020 (REV), PROTECT B, 2020 (REV), RECOVERY, 2020 (REV), REMAP-CAP-HCQ, 2020 (REV), SOLIDARITY (WHO study) HCQ, 2020 (REV), Tang, 2020 (REV) 20 0% 8,188 moderate low deaths (time to event analysis only)detailed results NOR-Solidarity (hydroxychloroquine), 2021 (REV) 0.32 [0.03; 3.45]
RECOVERY, 2020 (REV) 0.92 [0.81; 1.03]
SOLIDARITY (WHO study) HCQ, 2020 (REV) 0.84 [0.63; 1.12]
0.90 [0.81 ; 1.01 ] NOR-Solidarity (hydroxychloroquine), 2021 (REV), RECOVERY, 2020 (REV), SOLIDARITY (WHO study) HCQ, 2020 (REV) 3 0% 6,681 moderate not evaluable clinical deteriorationdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV) 0.83 [0.47; 1.45]
Kamran, 2020 (REV) 1.05 [0.36; 3.08]
Zhaowei Chen, 2020 (REV) 9.04 [0.46; 178.86]
0.98 [0.52 ; 1.86 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV), Kamran, 2020 (REV), Zhaowei Chen, 2020 (REV) 3 18% 894 moderate not evaluable clinical improvement (14-day)detailed results Chen, 2020 (REV) 1.79 [0.40; 7.91]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV) 1.21 [0.69; 2.12]
1.27 [0.75 ; 2.14 ] Chen, 2020 (REV), Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV) 2 0% 481 moderate not evaluable clinical improvement (time to event analysis only)detailed results FACCT Trial, 2021 (REV) 1.18 [0.86; 1.62]
1.18 [0.86 ; 1.62 ] FACCT Trial, 2021 (REV) 1 0% 254 NA not evaluable death or ventilationdetailed results RECOVERY, 2020 (REV) 0.88 [0.79; 0.97]
SOLIDARITY (WHO study) HCQ, 2020 (REV) 0.90 [0.71; 1.15]
0.88 [0.80 ; 0.97 ] RECOVERY, 2020 (REV), SOLIDARITY (WHO study) HCQ, 2020 (REV) 2 0% 5,776 moderate not evaluable hospital dischargedetailed results FACCT Trial, 2021 (REV) 1.14 [0.83; 1.57]
1.14 [0.83 ; 1.57 ] FACCT Trial, 2021 (REV) 1 0% 254 NA not evaluable radiologic improvement (7-day)detailed results Zhaowei Chen, 2020 (REV) 0.29 [0.09; 0.91]
0.29 [0.09 ; 0.91 ] Zhaowei Chen, 2020 (REV) 1 0% 62 NA not evaluable viral clearance detailed results HC-nCoV (Shanghai), 2020 (REV) 2.15 [0.17; 26.67]
2.15 [0.17 ; 26.67 ] HC-nCoV (Shanghai), 2020 (REV) 1 0% 30 NA not evaluable viral clearance by day 14detailed results Chen, 2020 (REV) 0.71 [0.13; 3.87]
0.71 [0.13 ; 3.87 ] Chen, 2020 (REV) 1 0% 33 NA not evaluable ICU admissiondetailed results Abd-Elsalam, 2020 (REV) 1.21 [0.51; 2.85]
FACCT Trial, 2021 (REV) 0.70 [0.39; 1.26]
0.84 [0.51 ; 1.38 ] Abd-Elsalam, 2020 (REV), FACCT Trial, 2021 (REV) 2 4% 448 moderate not evaluable cardiac arrestdetailed results SOLIDARITY (WHO study) HCQ, 2020 (REV) 0.52 [0.10; 2.85]
0.52 [0.10 ; 2.85 ] SOLIDARITY (WHO study) HCQ, 2020 (REV) 1 0% 1,853 NA not evaluable adverse eventsdetailed results ChiCTR2000030054-HCQ (Chen), 2020 (REV) 0.20 [0.03; 1.18]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV) 1.14 [0.38; 3.42]
HC-nCoV (Shanghai), 2020 (REV) 0.69 [0.12; 3.79]
RECOVERY, 2020 (REV) 0.73 [0.53; 1.02]
Tang, 2020 (REV) 0.10 [0.01; 2.00]
0.70 [0.46 ; 1.05 ] ChiCTR2000030054-HCQ (Chen), 2020 (REV), Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV), HC-nCoV (Shanghai), 2020 (REV), RECOVERY, 2020 (REV), Tang, 2020 (REV) 5 7% 5,258 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-27 14:32 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 651
- roots T: 651
